ZA943593B - Pharmaceutical composition of a 5-HT3 receptor antagonist for rectal administration - Google Patents
Pharmaceutical composition of a 5-HT3 receptor antagonist for rectal administrationInfo
- Publication number
- ZA943593B ZA943593B ZA943593A ZA943593A ZA943593B ZA 943593 B ZA943593 B ZA 943593B ZA 943593 A ZA943593 A ZA 943593A ZA 943593 A ZA943593 A ZA 943593A ZA 943593 B ZA943593 B ZA 943593B
- Authority
- ZA
- South Africa
- Prior art keywords
- pharmaceutical composition
- receptor antagonist
- rectal administration
- rectal
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939310756A GB9310756D0 (en) | 1993-05-25 | 1993-05-25 | Compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA943593B true ZA943593B (en) | 1995-02-13 |
Family
ID=10736089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA943593A ZA943593B (en) | 1993-05-25 | 1994-05-24 | Pharmaceutical composition of a 5-HT3 receptor antagonist for rectal administration |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US5741806A (xx) |
| EP (1) | EP0700290B1 (xx) |
| JP (1) | JP2965703B2 (xx) |
| KR (1) | KR100297212B1 (xx) |
| CN (1) | CN1106194C (xx) |
| AP (1) | AP544A (xx) |
| AT (1) | ATE183643T1 (xx) |
| AU (1) | AU680918B2 (xx) |
| BE (1) | BE1007158A3 (xx) |
| BR (1) | BR1100046A (xx) |
| CA (1) | CA2162919C (xx) |
| CO (1) | CO4230094A1 (xx) |
| CY (1) | CY2411B1 (xx) |
| CZ (1) | CZ291041B6 (xx) |
| DE (1) | DE69420266T2 (xx) |
| DK (1) | DK0700290T3 (xx) |
| EC (1) | ECSP941088A (xx) |
| ES (1) | ES2136198T3 (xx) |
| FR (1) | FR2705569B1 (xx) |
| GB (2) | GB9310756D0 (xx) |
| GR (1) | GR3031669T3 (xx) |
| HR (2) | HRP940315B1 (xx) |
| HU (1) | HU227121B1 (xx) |
| IE (1) | IE80632B1 (xx) |
| IL (1) | IL109749A (xx) |
| IS (1) | IS1868B (xx) |
| IT (1) | IT1272990B (xx) |
| MY (1) | MY111445A (xx) |
| NO (1) | NO306448B1 (xx) |
| NZ (1) | NZ267415A (xx) |
| PE (1) | PE13395A1 (xx) |
| PL (1) | PL175578B1 (xx) |
| RU (1) | RU2132684C1 (xx) |
| SA (1) | SA94150003B1 (xx) |
| SG (1) | SG48119A1 (xx) |
| SI (1) | SI0700290T1 (xx) |
| WO (1) | WO1994027599A1 (xx) |
| ZA (1) | ZA943593B (xx) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1464333A3 (en) * | 1998-06-15 | 2004-12-15 | Sepracor Inc. | Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders |
| EP1468685A3 (en) * | 1998-06-15 | 2004-12-15 | Sepracor Inc. | Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders |
| SK19062000A3 (sk) * | 1998-06-15 | 2001-07-10 | Sepracor, Inc. | Použitie (-)-norcisapridu alebo jeho farmaceuticky prijateľnej soli, v podstate bez jeho (+) stereoizoméru, na liečenie apnoe, bulímie a iných porúch |
| BR9911299A (pt) * | 1998-06-15 | 2001-03-13 | Sepracor Inc | Processos para tratar bulimia, para tratar distúrbios mediados por atividade vagal, para tratar sìndrome de intestino irritável, para tratar bradicardia ou bradiarritmia, para tratar asma, para tratar incontinência urinária, para tratar apnéia ou distúrbios de apnéia,ou distúrbios de apnéia, para prevenir ou controlar bulimia, distúrbios mediados por atividade vagal, sìndrome de intestino irritável, bradicardia ou bradiarritmia, asma, incontinência urinária, e, apnéia ou distúrbios da apnéia, em um paciente |
| US6362202B1 (en) | 1999-03-02 | 2002-03-26 | Sepracor Inc. | Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists |
| US6353005B1 (en) | 1999-03-02 | 2002-03-05 | Sepracor, Inc. | Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist |
| BR0112969A (pt) * | 2000-08-04 | 2004-06-22 | Dmi Biosciences Inc | Método de utilização de dicetopiperazinas e composições contendo-as |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4695578A (en) * | 1984-01-25 | 1987-09-22 | Glaxo Group Limited | 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances |
| DE3502508A1 (de) * | 1984-01-25 | 1985-08-14 | Glaxo Group Ltd., London | Heterocyclische verbindungen |
| GB8627909D0 (en) * | 1986-11-21 | 1986-12-31 | Glaxo Group Ltd | Medicaments |
| GB8816187D0 (en) * | 1988-07-07 | 1988-08-10 | Glaxo Group Ltd | Medicaments |
| US5166145A (en) * | 1990-09-10 | 1992-11-24 | Alza Corporation | Antiemetic therapy |
-
1993
- 1993-05-25 GB GB939310756A patent/GB9310756D0/en active Pending
-
1994
- 1994-05-17 EC EC1994001088A patent/ECSP941088A/es unknown
- 1994-05-17 SG SG1996007139A patent/SG48119A1/en unknown
- 1994-05-17 GB GB9409835A patent/GB2279008B/en not_active Expired - Lifetime
- 1994-05-19 IS IS4168A patent/IS1868B/is unknown
- 1994-05-20 MY MYPI94001305A patent/MY111445A/en unknown
- 1994-05-23 HR HR940315A patent/HRP940315B1/xx not_active IP Right Cessation
- 1994-05-23 PE PE1994242905A patent/PE13395A1/es not_active IP Right Cessation
- 1994-05-23 CO CO94021615A patent/CO4230094A1/es unknown
- 1994-05-23 IE IE940420A patent/IE80632B1/en not_active IP Right Cessation
- 1994-05-23 AP APAP/P/1994/000643A patent/AP544A/en active
- 1994-05-24 CZ CZ19953085A patent/CZ291041B6/cs not_active IP Right Cessation
- 1994-05-24 IT ITRM940322A patent/IT1272990B/it active IP Right Grant
- 1994-05-24 RU RU95122578A patent/RU2132684C1/ru active
- 1994-05-24 SI SI9430263T patent/SI0700290T1/xx unknown
- 1994-05-24 CA CA002162919A patent/CA2162919C/en not_active Expired - Lifetime
- 1994-05-24 WO PCT/EP1994/001652 patent/WO1994027599A1/en active IP Right Grant
- 1994-05-24 DE DE69420266T patent/DE69420266T2/de not_active Expired - Lifetime
- 1994-05-24 CN CN94192243A patent/CN1106194C/zh not_active Expired - Lifetime
- 1994-05-24 EP EP94918355A patent/EP0700290B1/en not_active Expired - Lifetime
- 1994-05-24 AU AU69709/94A patent/AU680918B2/en not_active Expired
- 1994-05-24 US US08/537,950 patent/US5741806A/en not_active Expired - Lifetime
- 1994-05-24 KR KR1019950705280A patent/KR100297212B1/ko not_active IP Right Cessation
- 1994-05-24 ZA ZA943593A patent/ZA943593B/xx unknown
- 1994-05-24 AT AT94918355T patent/ATE183643T1/de active
- 1994-05-24 IL IL10974994A patent/IL109749A/en not_active IP Right Cessation
- 1994-05-24 PL PL94311721A patent/PL175578B1/pl unknown
- 1994-05-24 HU HU9503375A patent/HU227121B1/hu unknown
- 1994-05-24 FR FR9406252A patent/FR2705569B1/fr not_active Expired - Lifetime
- 1994-05-24 NZ NZ267415A patent/NZ267415A/en not_active IP Right Cessation
- 1994-05-24 BE BE9400528A patent/BE1007158A3/fr not_active IP Right Cessation
- 1994-05-24 DK DK94918355T patent/DK0700290T3/da active
- 1994-05-24 ES ES94918355T patent/ES2136198T3/es not_active Expired - Lifetime
- 1994-05-24 JP JP7500204A patent/JP2965703B2/ja not_active Expired - Lifetime
- 1994-06-12 SA SA94150003A patent/SA94150003B1/ar unknown
-
1995
- 1995-11-24 NO NO954783A patent/NO306448B1/no not_active IP Right Cessation
-
1996
- 1996-09-19 BR BR1100046-5A patent/BR1100046A/pt active IP Right Grant
-
1997
- 1997-06-09 HR HR970315A patent/HRP970315A2/hr not_active Application Discontinuation
-
1999
- 1999-10-27 GR GR990402759T patent/GR3031669T3/el unknown
-
2000
- 2000-06-06 CY CY0000022A patent/CY2411B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0687472A3 (en) | Potentiation of a drug by a serotonin 1A receptor antagonist | |
| EP0714663A3 (en) | Potentiation of drug responses by serotonin 1A receptor antagonists | |
| GB9518113D0 (en) | Polymorphic form of a tachykinin receptor antagonist | |
| HUP9603298A3 (en) | Heterocyclic compounds having tachykinin receptor antagonist activity, their preparation, and their use for the preparation of pharmaceutical compositions | |
| IL97513A0 (en) | A pharmaceutical composition containing a thromboxane a2 receptor antagonist prostaglandin analog | |
| IL110503A (en) | Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation and pharmaceutical compositions containing them | |
| IL111007A0 (en) | Composition containing rapamycin for oral administration | |
| HUP9701714A3 (en) | Indole derivatives neuropeptide y receptor antagonists, use thereof and pharmaceutical compositions containing these compounds | |
| AU5093293A (en) | Alicyclic compounds as tachykinin receptor antagonists | |
| HUP9901296A3 (en) | Substituted piperidine derivatives as nmda receptor antagonists and pharmaceutical compositions containing them | |
| IL117728A0 (en) | Pharmaceutical compositions for transdermal administration | |
| IL131818A0 (en) | Pharmaceutical composition for oral administration of a n-piperidino-3-pyrazolecarboxamide derivative its salts and their solvates | |
| NO302216B1 (no) | Farmasöytisk doseringsform med nullte ordens frigivelse av en kalsiumantagonist av dihydropyridintypen | |
| AU4718093A (en) | Substituted amines as tachykinin receptor antagonists | |
| HUP9801323A3 (en) | Use of benzotiophene derivatives for producing pharmaceutical compositions a for inhibiting cell-cell adhesion | |
| HUP0004008A3 (en) | Polymorphic form of a morpholine derivative having tachykinin receptor antagonist activity and pharmaceutical compositions containing the same | |
| IL101858A0 (en) | Pharmaceutical compositions containing a combination of an angiotensin-ii antagonist and a calcium channel blocker | |
| HUT74746A (en) | Pharmaceutical compositions containing p antagonist | |
| DK92286D0 (da) | Farmaceutisk praeparat indeholdende en histamin h2-receptorantagonist | |
| PL330195A1 (en) | Antagonist of dopamine d4 receptor | |
| GR900100015A (en) | Dosage form for acalcium antagonist supply | |
| HU912921D0 (en) | Cck antagonist 3-aryl-4(3h)-quinazolinones and pharmaceutical preparatives containing said compounds | |
| ZA943593B (en) | Pharmaceutical composition of a 5-HT3 receptor antagonist for rectal administration | |
| FI944534A (fi) | Rapamysiinikoostumuksia oraalisesti annettaviksi | |
| IL102372A0 (en) | Pharmaceutical composition containing a non-n-methyl-d-aspartate antagonist |